A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors

Trial Profile

A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 May 2017

At a glance

  • Drugs Ramucirumab (Primary)
  • Indications CNS cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 18 May 2017 Planned End Date changed from 1 Oct 2018 to 1 Jan 2019.
    • 18 May 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Jan 2019.
    • 12 Dec 2016 Planned End Date changed from 1 May 2017 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top